Oculus Innovative Sciences Inc (NASDAQ:OCLS)

CAPS Rating: 2 out of 5

The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.

Results 1 - 12 of 12

Recs

0
Member Avatar AnsgarJohn (98.18) Submitted: 1/26/2015 10:01:15 PM : Outperform Start Price: $0.83 OCLS Score: -1.02

this stinks to high heaven, not EBIT but lots of EPS. Insider buying by CFO, selling shares (increase in shares outstanding), lots of cash... zzlangerhans red thumb.
Half of book value...
Educational pick. Oculus Innovative Sciences http://www.gurufocus.com/financials/OCLS

Recs

0
Member Avatar s2dbaker (88.70) Submitted: 7/22/2014 9:42:39 PM : Outperform Start Price: $2.90 OCLS Score: -72.90

This stock will never go down again.

Recs

1
Member Avatar chris293 (87.94) Submitted: 11/10/2013 8:06:57 PM : Underperform Start Price: $2.72 OCLS Score: +82.32

OCLS seems to have a funny problem, when they have increases in revenue, they company seems to have bigger losses in earning per share. Can anyone explain this?

Recs

0
Member Avatar kirpi4 (< 20) Submitted: 7/12/2013 12:56:03 PM : Outperform Start Price: $3.04 OCLS Score: -93.00

will grow up

Recs

0
Member Avatar zjmoser (< 20) Submitted: 4/2/2013 3:39:56 AM : Outperform Start Price: $3.46 OCLS Score: -104.38

Growth prospects

Recs

1
Member Avatar Casew (< 20) Submitted: 2/25/2012 10:53:31 AM : Outperform Start Price: $9.17 OCLS Score: -138.31

When this company went public back in 2007, it's share price peaked at around $11. It has steadily gone down since then and now typically trades at a little over $1.

What's interesting about this is that it's revenue has actually grown from $94,000 in 2004 to $9,754,000 in 2011. Expenses have not grown with the revenue, it has high profit margins, and excellent management.

This stock is dramatically undervalued, currently selling at the bargain price of $1.26. One day this company is going to catch Wall Street's eye, and when that happens we'll see the share price go through the roof.

Recs

0
Member Avatar ctsolomonmd (< 20) Submitted: 2/13/2012 1:20:58 PM : Outperform Start Price: $9.17 OCLS Score: -139.11

totally under the radar. positive free cash flow per share. Huge market with disruptive technology. Medicare won't pay for wound infections and this company has a reasonable remedy. I own this stock.

Recs

0
Member Avatar HollowMountain (< 20) Submitted: 2/6/2011 2:12:45 PM : Outperform Start Price: $13.51 OCLS Score: -146.27

This company has had some problems in the past, but it sells a brand that is important in the healthcare field and is only going to expand in business as people look for cheaper alternatives to expensive prescription medications.

Recs

0
Member Avatar targetphil3 (< 20) Submitted: 10/14/2010 10:38:17 PM : Outperform Start Price: $12.25 OCLS Score: -162.60

wonder if new acne meds do good in mexico? I actually hope they market to military for wound treatments.

Recs

1
Member Avatar HGPD99 (< 20) Submitted: 9/20/2010 11:43:45 AM : Outperform Start Price: $10.64 OCLS Score: -167.27

Amazing new products in the medical field.

Recs

1
Member Avatar Hanks98 (< 20) Submitted: 8/6/2007 5:47:18 PM : Outperform Start Price: $67.41 OCLS Score: -143.16

Announcing their final FDA approval in September and the distribution deals will follow. This stock is a 10 bagger over the next year.

Recs

0
Member Avatar IndexTrojan (58.46) Submitted: 1/26/2007 1:03:55 PM : Underperform Start Price: $55.44 OCLS Score: +148.22

Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in acute and chronic wounds. Oculus’ platform technology, called Microcyn

Results 1 - 12 of 12

Featured Broker Partners


Advertisement